Short Interest in BioCardia, Inc. (NASDAQ:BCDA) Decreases By 62.1%

BioCardia, Inc. (NASDAQ:BCDA) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 50,000 shares, a decline of 62.1% from the September 30th total of 132,100 shares. Based on an average daily trading volume, of 821,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.8% of the shares of the company are short sold.

BioCardia Trading Up 0.8 %

Shares of BCDA traded up $0.02 during mid-day trading on Friday, reaching $2.42. The company had a trading volume of 25,889 shares, compared to its average volume of 313,940. The stock has a market cap of $4.41 million, a price-to-earnings ratio of -0.34 and a beta of 1.26. The firm has a fifty day simple moving average of $2.75 and a 200-day simple moving average of $3.66. BioCardia has a fifty-two week low of $1.96 and a fifty-two week high of $23.25.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.78). As a group, equities analysts predict that BioCardia will post -5.06 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of BioCardia from $4.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 16th.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.